GLAXOSMITHKLINE PLC
GSK
 Delayed - 07/27 11:38:11 am |
|
| 1399.2GBX | -0.04% |
Business Summary
| Healthcare | ||||
 | Pharmaceuticals & Medical Research | |||
| Pharmaceuticals | |||
| Pharmaceuticals | |||
| Other Pharmaceuticals | |||
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Number of employees : 94 066 people.
Number of employees : 94 066 people.
Sales per Business
| 2019 | 2020 | ||||
| Pharmaceuticals | 17 554.00 | 52% | 17 056.00 | 50% | |
| Consumer Healthcare | 8 995.00 | 26.6% | 10 033.00 | 29.4% | |
| Vaccines | 7 157.00 | 21.2% | 6 982.00 | 20.5% | |
| Corporate and Other Unallocated | 48.00 | 0.1% | 28.00 | 0.1% | |
| GBP in Million | |||||
Sales per region
| 2019 | 2020 | ||||
| United States | 13 890.00 | 41.2% | 14 556.00 | 42.7% | |
| Rest of World | 11 795.00 | 34.9% | 11 379.00 | 33.4% | |
| Europe | 7 127.00 | 21.1% | 7 184.00 | 21.1% | |
| United Kingdom | 942.00 | 2.8% | 980.00 | 2.9% | |
| GBP in Million | |||||
Managers
| Name | Title |
| Emma N. Walmsley | Chief Executive Officer & Executive Director |
| Iain James Mackay | Chief Financial Officer & Executive Director |
| Jonathan Richard Symonds | Non-Executive Chairman |
| Karenann K. Terrell | Chief Digital & Technology Officer |
| Hal V. Barron | Executive Director & Chief Scientific Officer |
| Jon Ellis | VP & Head-Technology Business Development |
| Amy Altshul | SVP-Legal, Research & Development |
| Nick Hirons | Senior Vice President-Global Ethics & Compliance |
| Lynn Laverty Elsenhans | Independent Non-Executive Director |
| Urs Rohner | Independent Non-Executive Director |
| Shareholders |
| Name | Equities | % |
| The Vanguard Group, Inc. | 138,178,000 | 2.75% |
| BlackRock Fund Advisors | 131,211,690 | 2.61% |
| BlackRock Investment Management (UK) Ltd. | 128,982,522 | 2.56% |
| Norges Bank Investment Management | 120,993,000 | 2.40% |
| Dodge & Cox | 99,377,874 | 1.98% |
| Capital Research & Management Co. (Global Investors) | 85,408,294 | 1.70% |
| BlackRock Advisors (UK) Ltd. | 70,095,800 | 1.39% |
| Schroder Investment Management Ltd. | 67,632,198 | 1.34% |
| State Street Global Advisors Ltd. | 66,693,562 | 1.33% |
| SSgA Funds Management, Inc. | 52,581,000 | 1.05% |
Company contact information
980 Great West Road
TW8 9GS Brentford, Greater London
Phone : +44 (0)20 8047 5000
Fax : +44 (0)20 8047 7807
web site : http://www.gsk.com
TW8 9GS Brentford, Greater London
Phone : +44 (0)20 8047 5000
Fax : +44 (0)20 8047 7807
web site : http://www.gsk.com
Markets and indexes
| - Main Market |
| - FTSE 100 / FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50 |
Stock Exchange Codes
| - Bloomberg Code : | GSK:LN |
| - Reuters Code : | GSK.L |
| - Datastream Code : | GSK |
Sector Other Pharmaceuticals
| 1st jan. | Capi. (M$) | ||
 | |||
| GLAXOSMITHKLINE PLC | 6.03% | 96 813 | |
| |||
| JOHNSON & JOHNSON | 9.21% | 452 602 | |
| ROCHE HOLDING AG | 11.50% | 327 852 | |
| PFIZER, INC. | 13.58% | 234 040 | |
| NOVARTIS AG | -0.17% | 221 954 | |
| ELI LILLY AND COMPANY | 44.05% | 221 084 | |
| ABBVIE INC. | 9.93% | 208 043 | |
| NOVO NORDISK A/S | 31.49% | 204 273 | |
| MERCK & CO., INC. | -5.57% | 195 576 | |
| ASTRAZENECA PLC | 13.22% | 177 536 | |
| BRISTOL-MYERS SQUIBB COMPANY | 9.12% | 151 141 | |
| AMGEN INC. | 6.59% | 140 812 | |
| SANOFI | 11.28% | 129 373 | |
| GLAXOSMITHKLINE PLC | 4.31% | 96 813 | |
| ALLERGAN PLC | 0.97% | 63 659 | |
| CHUGAI PHARMACEUTICAL CO., LTD. | -24.11% | 62 249 | |
| BAYER AG | 6.68% | 59 604 | |
| JIANGSU HENGRUI MEDICINE CO., LTD. | -36.24% | 58 191 | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | -1.46% | 52 508 | |
| DAIICHI SANKYO COMPANY, LIMITED | -36.17% | 39 204 | |
| ASTELLAS PHARMA INC. | 20.55% | 32 281 | |
Brand Portfolio
